IRIDEX Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4626841013
USD
0.93
0.01 (0.67%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About IRIDEX Corp. stock-summary
stock-summary
IRIDEX Corp.
Pharmaceuticals & Biotechnology
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.
Company Coordinates stock-summary
Company Details
1212 Terra Bella Ave , MOUNTAIN VIEW CA : 94043-1824
stock-summary
Tel: 1 650 94047001 415 9375404
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (7.0%)

Foreign Institutions

Held by 6 Foreign Institutions (0.5%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Robert Gunst
Independent Chairman of the Board
Mr. David Bruce
President, Chief Executive Officer, Director
Ms. Doris Engibous
Independent Director
Dr. Robert Grove
Independent Director
Mr. Kenneth Ludlum
Independent Director
Mr. Scott Shuda
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
14 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 23 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.32

stock-summary
Return on Equity

-89.90%

stock-summary
Price to Book

3.87